Full Text View
Tabular View
No Study Results Posted
Related Studies
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
This study is ongoing, but not recruiting participants.
Study NCT01577550   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on April 10, 2012.   Last Updated on June 13, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Psoriasis
More general conditions related to this trial
Skin Diseases
Skin Diseases, Papulosquamous
Interventions listed in this trial
BI 655066 (very high i.v. dose)
Placebo, i.v.
BI 655066 (high s.c. dose)
BI 655066 (low i.v. dose)
BI 655066 (high medium i.v. dose)
BI 655066 (very low i.v. dose)
BI 655066 (low s.c. dose)
BI 655066 (high i.v. dose)
Placebo, s.c.
BI 655066 (low medium i.v. dose)
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services